STIMULI RESPONSIVE NANOMEDICINE FOR INFLAMMATORY BOWEL DISEASE: EXPLOITING THE PATHOLOGICAL MICROENVIRONMENT FOR TARGETED DRUG DELIVERY

Introduction IBD is a long-lasting, recurring condition that mainly includes Crohn's disease and ulcerative colitis. It causes ongoing inflammation in the intestines, changes how the immune system works, harms the lining of the gut, and upsets the balance of the gut environment. Even though the way these drugs are given has been improved for treating these diseases, they still aren't very specific to where they're needed, can cause serious side effects, and may lose their effect early on because they don't target the diseased parts of the bowel very precisely. Despite these drawbacks, nanomedicine also helps with stabilizing resistant drugs, targeting the intestines, absorption, and controlled release. Moreover, many pathological changes within IBD relate to abnormal microenvironments (for example, higher levels of ROS, dysfunctional mucus and epithelial barriers, pH changes, abnormal enzymatic activity, disturbance of the redox system and microbial imbalance), providing potential endogenous markers for site-specific delivery of therapeutic agents in the context of stimulus-responsive (e.g. pH, ROS, enzyme, redox, microbiota and multi-responsive) delivery systems. Here, we'll look at the idea of microenvironment-responsive nanomedicine for IBD, covering its design, how it releases drugs, its effects on the disease, and how it can slow progression in the inflamed gut while reducing side effects and overall toxicity, along with discussing important design issues like targeted recognition, nanocarrier stability, biocompatibility, reproducibility, and how to move from preclinical to clinical use. Using natural disease markers to respond specifically fits with new approaches in IBD treatment.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-19
DOI
https://doi.org/10.5281/zenodo.24362166
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

STIMULI RESPONSIVE NANOMEDICINE FOR INFLAMMATORY BOWEL DISEASE: EXPLOITING THE PATHOLOGICAL MICROENVIRONMENT FOR TARGETED DRUG DELIVERY

Arnab Bagchi, Pempo Lhamu Bhutia, Pragya Rani, Rozila Rai et al.
Zenodo (CERN European Organization for Nuclear Research)
Inflammatory Bowel Disease
article

STIMULI RESPONSIVE NANOMEDICINE FOR INFLAMMATORY BOWEL DISEASE: EXPLOITING THE PATHOLOGICAL MICROENVIRONMENT FOR TARGETED DRUG DELIVERY

Arnab Bagchi, Pempo Lhamu Bhutia, Pragya Rani, Rozila Rai, Priya Pandey, Nirmika Gurung
article en

Abstract

Introduction IBD is a long-lasting, recurring condition that mainly includes Crohn's disease and ulcerative colitis. It causes ongoing inflammation in the intestines, changes how the immune system works, harms the lining of the gut, and upsets the balance of the gut environment. Even though the way these drugs are given has been improved for treating these diseases, they still aren't very specific to where they're needed, can cause serious side effects, and may lose their effect early on because they don't target the diseased parts of the bowel very precisely. Despite these drawbacks, nanomedicine also helps with stabilizing resistant drugs, targeting the intestines, absorption, and controlled release. Moreover, many pathological changes within IBD relate to abnormal microenvironments (for example, higher levels of ROS, dysfunctional mucus and epithelial barriers, pH changes, abnormal enzymatic activity, disturbance of the redox system and microbial imbalance), providing potential endogenous markers for site-specific delivery of therapeutic agents in the context of stimulus-responsive (e.g. pH, ROS, enzyme, redox, microbiota and multi-responsive) delivery systems. Here, we'll look at the idea of microenvironment-responsive nanomedicine for IBD, covering its design, how it releases drugs, its effects on the disease, and how it can slow progression in the inflamed gut while reducing side effects and overall toxicity, along with discussing important design issues like targeted recognition, nanocarrier stability, biocompatibility, reproducibility, and how to move from preclinical to clinical use. Using natural disease markers to respond specifically fits with new approaches in IBD treatment.

Zenodo (CERN European Organization for Nuclear Research)
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon